AZBio Member Senestech has entered into an exclusive licensing agreement with Neogen to manufacture and market a rodent control product that uses fertility control to manage rat populations.Continue reading→

An interdisciplinary team of UA researchers has received a $2.098 million grant to study recovery of language in the early phase of recovery after a stroke.Continue reading→

TGen Concussion Research Fund is first under ACF’s new Jerry Colangelo Center for Sports PhilanthropyContinue reading→

TUCSON, AZ– – Today HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of 2,275 human microRNAs (miRNAs) described in the miRBase v20 database.Continue reading→

VisionGate Inc., an in vitro diagnostics company that has developed the patented Cell-CT^®,a 3D cell imaging platform being utilized in early disease detection, recently added three new esteemed business leaders to its Board of Directors. The directors come on board at a pivotal time for VisionGate, as its revolutionary, non-invasive test for the early detection of lung cancer – LuCED^® – is poised to enter the market.Continue reading→

Construction of Biosciences Partnership Building Set to BeginContinue reading→

TUCSON, Ariz. – Andrew S. Kraft, MD, a nationally recognized prostate cancer physician-scientist and cancer center administrator, has been named the Sydney E. Salmon endowed chair and Director of the University of Arizona Cancer Center and Associate Vice President for Oncology Programs for the University of Arizona Health Sciences Center. In addition to his Cancer Center leadership role, Dr. Kraft joins the University as tenured Professor of Medicine in the Department of Medicine, Division of Hematology/Oncology and Senior Associate Dean for Translational Research in the College of Medicine.Continue reading→